BeyondSpring and Leading Cancer Center Present Poster Highlighting Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCT
07 Juin 2023 - 2:00PM
BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”),
a global clinical-stage biopharmaceutical company focused on using
a groundbreaking technology platform for drug discovery and
developing innovative therapies to improve clinical outcomes for
patients with high unmet medical needs, today announced new data
from a Phase 1 investigator initiated study highlighting a
reduction in chemotherapy-induced infectious neutropenic fever with
lead asset Plinabulin in combination with pegfilgrastim in multiple
myeloma (MM) patients who underwent autologous hematopoietic stem
cell transplantation (AHCT) and received a high dose of melphalan,
a type of chemotherapy and one of the most active treatments for MM
(NCT05130827). BeyondSpring and Memorial Sloan Kettering Cancer
Center (MSK) presented the data at the 2023 American Society of
Clinical Oncology (ASCO) Annual Meeting.
Between January 2022 and February 2023, 15
patients with a median age of 64 received Plinabulin after a high
dose of melphalan. One dose of 40mg of Plinabulin was given to
patients via IV infusion one to three hours after stem cell
infusion on Day 0, and 6mg of pegfilgrastim was given on Day 1.
The Plinabulin and pegfilgrastim combination
appears well tolerated without additional major toxicities post
AHCT. Although the combination did not decrease days of severe
neutropenia compared with historical data of pegfilgrastim alone,
the addition of Plinabulin potentially decreased other clinical
consequences:
- Reduced rate of
infection-related neutropenic fever: Out of 15 patients, 7
had no fevers and 1 had a true neutropenic fever;
- Reduced red blood cell
(RBC) transfusion: Median of zero RBC transfusion per
patient with the use of Plinabulin and pegfilgrastim;
- Reduced platelet
transfusion: Median of two platelet transfusions per
patient with the combination.
“The Plinabulin-pegfilgrastim combination
represents a new potential supportive care for MM patients
undergoing AHCT. From this pilot study, we saw a trend in the
combination in reducing infectious neutropenic fevers and RBC and
platelet transfusion requirements compared to historical
expectations, which are clinically important benefits,” said Dr.
Gunjan Shah, MD, MS, Assistant Attending Physician at MSK and
Principal Investigator of the trial.
About BeyondSpringBeyondSpring
(NASDAQ: BYSI) is a global clinical-stage biopharmaceutical company
focused on developing innovative therapies to improve clinical
outcomes for patients with high unmet medical needs. The Company is
advancing its first-in-class lead asset, Plinabulin, as a direct
anti-cancer agent in various cancer indications and to prevent
chemotherapy-induced neutropenia. Its pipeline also includes three
preclinical immuno-oncology assets. Additionally, BeyondSpring’s
subsidiary, SEED Therapeutics, leverages a proprietary targeted
protein degradation (TPD) drug discovery platform and has an
initial R&D collaboration with Eli Lilly. Learn more by
visiting https://beyondspringpharma.com, and follow us on LinkedIn
and Twitter.
Investor
Contact:IR@beyondspringpharma.com
Media
Contact:PR@beyondspringpharma.com
BeyondSpring (NASDAQ:BYSI)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
BeyondSpring (NASDAQ:BYSI)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024